Kyprolis(carfilzmomib) launched in late July 2012, net sales for the second quarter of 2013 were $61.0 million according to Onyx announcement.
Onyx want Patrys to initiate an Investigator-Sponsored Clincal Trial using PAT-SM6 in combination with Onyx Pharmaceuticals' carfilzomib
BECAUSE:
"In June 2013 an article in respect of the preclinical studies and phase I clinical trial conducted with PAT-SM6 on melanoma was published. The results of preclinical studies conducted in melanoma confirm that PAT-SM6 induces tumour cell death by interacting with GRP78 and LDL. Additional preclinical data in an aggressive and metastatic mouse model showed PAT-SM6 significantly suppressed or eliminated the development of secondary tumours in all treated mice. Furthermore, PAT-SM6 was safe and well tolerated in animal toxicology studies. The publication also includes an overview of the Phase I clinical trial in patients with melanoma which was completed in February 2012 meeting its primary endpoint of safety and showing early evidence that PAT-SM6 specifically targets melanoma tumours and causes cell death."
PAB Price at posting:
5.8¢ Sentiment: Buy Disclosure: Not Held
